Monte Rosa Therapeutics, Inc. Common Stock (GLUE) is a publicly traded Healthcare sector company. As of May 21, 2026, GLUE trades at $18.62 with a market cap of $1.52B and a P/E ratio of 0.00. GLUE moved +6.09% today. Year to date, GLUE is +29.51%; over the trailing twelve months it is +348.32%. Its 52-week range spans $3.50 to $25.77. Analyst consensus is strong buy with an average price target of $32.80. Rallies surfaces GLUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GLUE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GLUE recently traded at $18.62. Market cap is $1.52B. P/E ratio is 0.00. Revenue is $75.62M.
| Metric | Value |
|---|---|
| Price | $18.62 |
| Market Cap | $1.52B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.77 |
| 52-Week Low | $3.50 |
| Volume | 6 |
| Avg Volume | 0 |
| Revenue (TTM) | $75.62M |
| Net Income | $-72.70M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2024 | $75.62M | $-72.70M | $0.00 |
| 2023 | $0 | $-135.35M | $0.00 |
| 2022 | $0 | $-108.50M | $0.00 |
| 2021 | $0 | $-73.96M | $0.00 |
7 analysts cover GLUE: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.80.